Clinical Trial Update: Evaluating the Safety and Immunogenicity of a Live Attenuated West Nile Virus Vaccine for West Nile Encephalitis in Adults 50 to 65 Years of Age [Phase 1]

View source ↗

Summary

Phase 1 trial assessing safety and immunogenicity of a live attenuated West Nile virus vaccine in adults aged 50–65 has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• West Nile Encephalitis
• West Nile Virus Infection

Drugs mentioned

• West Nile Virus Vaccine (live attenuated) (West Nile virus vaccine, live attenuated)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: West Nile Virus | Phase 1 | Status: COMPLETED